Loading clinical trials...
Loading clinical trials...
Ticagrelor Versus Clopidogrel for Platelet Inhibition in Patients Undergoing Neurovascular Stenting for Intracranial Aneurysm
Part of interventional neuroradiology procedures for the treatment of selected cerebral aneurysms are now based on stenting. To reduce thromboembolic events, dual antiplatelet therapy (APT) combining aspirin and clopidogrel is proposed with close monitoring, since 1/3 of the patients are low responders due to variation of the biological response to clopidogrel . Ticagrelor is used by few teams but has never been evaluated in a randomized controlled trial. It could be an option for APT due to more reproducible response with less interindividual variability and reduced monitoring. The aim of this study is to demonstrate the interest of ticagrelor for the dual APT for platelet inhibition, in patients undergoing neurovascular stenting for cerebral aneurysm.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Fondation Ophtalmologique Adolphe de Rothschild
Paris, France
Start Date
December 1, 2015
Primary Completion Date
July 1, 2020
Completion Date
December 1, 2020
Last Updated
July 16, 2021
100
ACTUAL participants
Clopidogrel
DRUG
Ticagrelor
DRUG
aspirin
DRUG
Lead Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
NCT06972966
NCT06766422
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07438275